Category: Healthcare News

  • Rosarium Health Forms Home Modification Partnership with Anthem Medi-Cal

    Rosarium Health Forms Home Modification Partnership with Anthem Medi-Cal

    Yellow house icon connected with Ethernet cables on blue background, Smart home networking, internet, and IoT connectivity.

    Rosarium Health, a company enabling aging at home, announced Thursday that it is partnering with Anthem Medi-Cal to support home modifications for members.

    Through the new partnership with Anthem, Rosarium Health will be able to provide in-home assessments for patients who are at risk of falls. These assessments are performed by occupational and physical therapists and surface information about the person’s condition and the environment they live in. 

    Based on the assessment, Rosarium Health can make home modifications, such as accessible ramps and stair lifts. California’s Medi-Cal program covers certain home modifications for eligible members to address accessibility and safety needs, generally up to a $7,500 lifetime limit.

    Rosarium Health will also coordinate the documentation and benefit authorization process with Anthem. In addition, it manages home modification projects through completion by conducting the quality review and handling contractor payment.

    The partnership comes as the U.S. population ages and demand for services that help older adults remain safely at home grows. California in particular is affected by this, according to Cameron Carter, founder and CEO of Rosarium Health.

    “One thing about California is that it is one of the newer states that have kind of gone over the age acuity cliff in that there’s more individuals over 65 than under 18 in the state of California. … With Anthem specifically, one of the things we’re able to do with them is not only provide those modifications to help people age in place, but provide Anthem for the first time really a deeper understanding of the built environment their patient population is living in and wants to live in,” he said in an interview.

    Rosarium Health has several other partnerships with California insurers, including Health Net, Central California Alliance for Health, CalViva and Community Health Plan of Imperial Valley. The partnership with Anthem expands Rosarium’s reach across Los Angeles, Sacramento, San Francisco, Santa Clara, Fresno and Kern.

    To measure the success of the partnership, Rosarium will track emergency room visits and inpatient stays, total cost of care and satisfaction from members and caregivers, Carter said.

    Ultimately, the company aims to make home modification benefits as accessible as any other benefit, like dental or vision, Carter added.

    “We feel like modifying your home should be as accessible as [possible]. So that’s our north star, to make sure we can do it across any population that exists. … We want to make sure everyone has access to this benefit, just like if they wanted to go to the gym or if they wanted glasses, and we want to make sure that reality is consistent from coast to coast,” he said.

    Photo: JuSun, Getty Images

  • Early Voting Begins

    Early Voting Begins

    This week, Trump administration officials announced their latest efforts to trim what they identified as duplicative and ineligible enrollees from government health programs. They tied the efforts to the administration’s broader crackdown on waste, fraud, and abuse — just as some states are opening polling stations for early voting.

    The outcome of the midterm elections is expected to affect how and whether Congress addresses several healthcare issues during the lame-duck session, not the least of which is government spending. Plus, Health and Human Services Secretary Robert F. Kennedy Jr. unveiled a new initiative to identify vaccine injuries, complete with a ribbon-cutting ceremony at the National Institutes of Health.

    This week’s panelists are Mary Agnes Carey of KFF Health News, Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health, Sandhya Raman of Bloomberg Law, and Paige Winfield Cunningham of The Washington Sun.

    Among the takeaways from this week’s episode:

    • Federal health officials this week pointed to their efforts to cut Affordable Care Act plan subsidies from people who were dead or found to have duplicate coverage under government health programs. While they were careful to say that these cases were not fraud, they tied their housekeeping activities to the Trump administration’s broader crackdown on waste, fraud, and abuse — and made that point just as some states are beginning early voting.
    • The outcome of the midterm elections is expected to shape how Congress spends its time during the coming lame-duck session, with benefits or repercussions for health policy. Should the Democrats win control of one or both chambers, for instance, the party’s leaders could push to hold off on tackling government spending until they have more clout next year. Among the issues on the table are changes to the No Surprises Act, which has shielded patients from many bills but also has come under criticism for problems with the arbitration system it created.
    • And Kennedy is pursuing a new initiative on vaccine injuries, opening a designated clinic at the NIH. The federal health department has also proposed reimbursing medical professionals for reporting vaccine-related injuries.

    Also this week, KFF Health News’ Julie Rovner talks with Dan Weissmann, host of the healthcare podcast An Arm and a Leg, about the new and even more confusing landscape for Medicare enrollees as open enrollment begins.

    Plus, for “extra credit” the panelists suggest health policy stories they read this week that they think you should read, too:  

    Mary Agnes Carey: KFF Health News’ “People Say These Peptides Hurt Them. Their Stories Are Muffled in MAHA’s Push for Medical Freedom,” by Amy Maxmen.

    Sandhya Raman: Stat’s “Helen Branswell, Whose Reporting on Infectious Diseases and Public Health Drew Acclaim, Dies at 69,” by Andrew Joseph.

    Paige Winfield Cunningham: KFF Health News’ “AI, Tech Leaders Are Lobbying Trump Health Officials in a Government-Run Chat Room,” by Amanda Seitz, Maia Rosenfeld, and Darius Tahir.

    Joanne Kenen: On CBS News’ Face the Nation, host Margaret Brennan’s interview with Shyam Sankar, chief technology officer at Palantir. (Read the transcript here.) 

    Also mentioned in this week’s podcast:


    Click here to find all our podcasts.

    And subscribe to “What the Health? From KFF Health News” on Apple Podcasts, Spotify, the NPR app, YouTube, Pocket Casts, or wherever you listen to podcasts.

  • AI Biotech Iambic Gets $150M in IPO Cash for ‘Molecular Superintelligence’ Drug R&D

    AI Biotech Iambic Gets $150M in IPO Cash for ‘Molecular Superintelligence’ Drug R&D

    Iambic Therapeutics, one of a growing number of biotech companies making artificial intelligence the center of its drug research strategy, raised $150 million in an IPO that will finance clinical development of cancer medicines designed to offer advantages over currently available therapies.

    Late Wednesday, Iambic priced more than 9.37 million shares at $16 each, which was the midpoint of the price range set in preliminary financial terms last week. Those shares began trading on the Nasdaq Thursday under the stock symbol “IAM.”

    San Diego-based Iambic has developed proprietary technologies that cover a molecule’s journey, everything from hit identification to clinical developability. The platform combines AI models with automated high-throughput experiments. According to the company, the continuous stream of experiments sharpens the platform’s predictions and search strategy as it learns from each test. Iambic calls its approach molecular superintelligence.

    “Our goal is to prove, program after program, that better technology leads to better medicines — and that a platform built around molecular superintelligence has the potential to systematically improve the historical cost, time, and probability of success that have constrained drug development,” Iambic said in the IPO filing.

    The Iambic platform can be used to discover new targets, but the company’s initial focus is developing drugs for validated cancer targets. The technology yielded lead program IAM1363, an inhibitor of the cancer protein HER2. It’s a target already drugged by antibodies, antibody drug conjugates (ADCs), and oral small molecules.

    In the filing, Iambic notes that HER2-driven tumors come with a high risk of spreading to the brain, out of reach of currently available therapies. IAM1363 is an oral small molecule designed to be selective to HER2 and to address multiple variants of this protein. It’s also designed to penetrate the brain to treat cancer that has metastasized there. Other potential advantages include overcoming drug resistance and reducing dose-limiting toxicities. Iambic says all of these drug properties were made possible by its molecular superintelligence platform.

    IAM1364 is currently in Phase 1/1b testing in patients with advanced or metastatic solid tumors harboring HER2-alterations. In the filing, Iambic said it expects to begin a registrational trial as early as next year. The pipeline also includes IAM217, a KIF18A inhibitor, and IAM-C1, a dual CDK2/4 inhibitor. Both are on a path to enter clinical testing.

    Iambic’s platform has attracted strategic partners such as AbbVie, Bayer, Jazz Pharmaceuticals, Lundbeck, Revolution Medicines, and Takeda Pharmaceutical. In the first half of this year, Iambic reported $12.7 million in collaboration revenue, up from $3.9 million in the same period last year.

    Iambic formed in 2019, co-founded by CEO Tom Miller, who was a Caltech chemistry professor, and Chief Technology Officer Fred Manby, a former chemistry professor at the University of Bristol. The molecular superintelligence technology was developed in partnership with Nvidia, which is also an investor in the company.

    Iambic emerged from stealth in 2023, revealing $100 million in funding and an early look at its preclinical pipeline. In its history as a private company, Iambic said it raised $536.5 million, most recently a $100 million round announced nearly a year ago. Catalio Capital Management is Iambic’s largest shareholder with an 8.9% post-IPO stake followed by Nexus Ventures’ 6.8% stake, according to the filing.

    As of the end of the second quarter of this year, Iambic reported its cash position was $207.8 million. Combined with the IPO proceeds, Iambic expects to have enough capital to fund operations into the fourth quarter of 2028. The company plans to spend $75 million to complete IAM1363’s Phase 1 test and to start one or more phase 2 tests that could support an application seeking accelerated FDA approval. IAM217 and IAM-C1 will receive about $15 million each for their respective Phase 1/2 tests.

    Iambic has also budgeted $20 million for continued investment in the superintelligence technology. In a 2023 interview, Miller described working with Iambic’s technology as an ongoing process.

    “The reality of AI is that this is an incredibly fast-moving field,” he said. “What is differentiated today requires ongoing innovation to continue to be innovative in three years, in five years.”

    Photo: koto_feja, Getty Images

  • Zocdoc acquires Sohar Health in latest push to scale tech infrastructure

    Zocdoc acquires Sohar Health in latest push to scale tech infrastructure

    It’s Zocdoc’s first acquisition in its nearly 20-year history as the online medical scheduling company works to scale its business. Sohar already provides insurance eligibility checks within Zocdoc’s appointment scheduling platform.

  • AMA releases governance framework for agentic AI in healthcare

    AMA releases governance framework for agentic AI in healthcare

    Industry groups have worked to release guidance on artificial intelligence-backed agents in the absence of federal regulation.

  • FDA ‘reset’ continues with new plan for reviewing rare disease drugs

    FDA ‘reset’ continues with new plan for reviewing rare disease drugs

    A revamped regulatory framework may give investors less of a “guessing game” as they weigh chances for drug approvals, one analyst said.

  • Why the Future of Healthcare Depends on Reinventing Primary Care Access

    Why the Future of Healthcare Depends on Reinventing Primary Care Access

    Healthcare is approaching an inflection point.

    The United States is projected to face a physician shortage of up to 86,000 doctors by 2036, including as many as 40,000 primary care physicians. Nearly 100 million Americans already lack adequate access to primary care, while average wait times for new patient appointments in many major markets stretch close to a month.

    The industry cannot solve that challenge simply by adding more scheduling apps or digital front doors.

    What is needed is a fundamentally different operating model for primary care, one designed around continuous engagement rather than episodic encounters.

    For decades, healthcare has largely been organized around visits: a patient gets sick, schedules an appointment, receives treatment, and exits the system until the next issue emerges. That model is increasingly unsustainable in a world defined by workforce shortages, rising chronic disease, and growing consumer expectations for always-on access and personalized experiences.

    The next generation of primary care will likely look far more connected, proactive, and intelligent.

    Increasingly, healthcare organizations are moving toward models that treat primary care as a continuous service capability rather than a series of disconnected appointments. In that future state, care is coordinated across digital, virtual, and in-person environments, supported by systems designed to help clinicians stay ahead of patient needs instead of reacting after problems escalate.

    Primary care no longer operates as a collection of isolated encounters. It functions as an integrated coordination layer designed to guide patients through the healthcare system more seamlessly and efficiently over time.

    That requires far more than digitizing existing workflows.

    It means building infrastructure capable of continuously synthesizing clinical, operational, and behavioral data to support what clinicians often describe as the “best next action” for a patient. In practice, that could involve identifying patients at rising risk before they require acute intervention, proactively recommending follow-up care, coordinating medication adherence, closing preventive care gaps, or helping direct patients toward the most appropriate site of care in real time.

    The goal is not to replace physicians. It is to extend their reach.

    Primary care teams today are overwhelmed by administrative complexity, fragmented systems, and increasing patient demand. Physicians often spend significant time navigating workflows, documentation requirements and disconnected platforms instead of focusing directly on patient care. Technology should reduce that burden, allowing clinicians to focus more attention on decision-making, relationships, and outcomes.

    That is where artificial intelligence may ultimately prove most valuable.

    Much of healthcare’s AI conversation has centered on chatbots, ambient documentation, and consumer-facing applications. Those technologies may improve portions of the experience, but the larger opportunity may lie deeper within healthcare’s operational infrastructure: coordinating care delivery dynamically across fragmented systems, surfacing timely insights within clinical workflows, and enabling more continuous patient engagement between visits.

    The broader challenge facing healthcare is no longer simply appointment availability. It is the industry’s ability to maintain longitudinal relationships with patients amid growing complexity and constrained clinical capacity.

    A more connected primary care model changes how healthcare organizations think about scale.

    Historically, scaling care often meant adding more physicians, facilities, and physical infrastructure. Given current workforce realities, the future may depend more on intelligently extending the capabilities of existing care teams through predictive insights, coordinated workflows, and continuous digital engagement.

    Patients could experience that shift in meaningful ways.

    Instead of navigating disconnected portals, referral chains, and scheduling systems, individuals may increasingly interact with healthcare through coordinated service models that anticipate needs, simplify navigation, and proactively guide care decisions. Primary care becomes less about isolated office visits and more about maintaining an ongoing connection to the healthcare system.

    That evolution also aligns closely with the economics of value-based care.

    As reimbursement models continue shifting toward outcomes and total cost management, healthcare organizations are increasingly incentivized to intervene earlier, reduce avoidable utilization, and improve long-term population health. Continuous primary care engagement becomes not only clinically important, but financially essential.

    Other industries already operate this way. Financial services, retail, and transportation evolved from transactional interactions into highly coordinated, data-driven service ecosystems. Healthcare is more complex and more personal, but consumer expectations are moving in the same direction.

    The organizations that lead the next era of healthcare may not be those with the most digital tools. They may be the ones that successfully rebuild primary care into a connected, intelligent, and continuously operating service designed around patients instead of processes.

    Photo: Nuthawut Somsuk, Getty Images

    Jean-Claude Saghbini

    Jean-Claude Saghbini is the Chief Technology Officer and President of Technology Services at Lumeris, where he integrates technological innovations, clinical processes, and operational excellence into leading value-based care solutions. He also oversees the efficient deployment of cutting-edge technologies like Generative AI to ensure optimal healthcare outcomes and client satisfaction. With over fifteen years of healthcare experience, Jean-Claude is dedicated to seamlessly integrating technology into clinical workflows to improve outcomes and reduce care variability and costs. Previously, he held key leadership roles at Wolters Kluwer Health and Cardinal Health, driving AI innovation, clinical decision support, and pioneering RFID solutions for medical device tracking.

    Jean-Claude holds a Master of Science in Engineering and Management from MIT Sloan School of Management, as well as a Master of Science degree and a bachelor’s degree in mechanical engineering from MIT and the University of Massachusetts, Dartmouth, respectively. He is also a holder of multiple patents in healthcare technology.

    This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.

  • Rush, Endeavor to merge into Illinois powerhouse

    Rush, Endeavor to merge into Illinois powerhouse

    Joining forces could give the two Chicagoland systems a leg up in the region’s fragmented and competitive hospital market — if regulators approve.

  • Truevis to set up ₹500 cr manufacturing plant in West Bengal

    Truevis to set up ₹500 cr manufacturing plant in West Bengal

    Kolkata: Truevis Technologies said it has been allotted 50 acres of land in Haldia by the West Bengal Government for its proposed medical equipment manufacturing plant.

    The facility will be Truevis’ second manufacturing base in India and its first in eastern India.

    The company stated that it foresees business of more than Rs 1,000 crore per year within five years of commissioning, with the new base helping it serve customers more efficiently, reduce import dependence for select product categories and support long-term expansion in India’s healthcare equipment sector.

    Planned capacity of the plant is more than 1,000 units of large medical equipment annually which includes, diagnostic imaging equipment, patient monitoring systems, radiotherapy and radiology equipment, and related components and assemblies.

    “Haldia offers a strong industrial base, port access, power and connectivity, alongside a clear government vision for manufacturing-led growth. We plan to manufacture large medical equipment in Bengal for markets across eastern India and beyond, gradually localise components and build a skilled technical workforce in partnership with local institutions,” a Truevis spokesperson said.

    Join the community of 2M+ industry professionals.

    Subscribe to Newsletter to get latest insights & analysis in your inbox.

    All about ETHealthworld industry right on your smartphone!

  • The Role of Hospital Stewardship to Improve Outcomes and Manage Costs

    The Role of Hospital Stewardship to Improve Outcomes and Manage Costs

    In a MedCity News webinar for Pharmacy Week 2026, pharmacy experts will explain why stewardship should be part of the conversation about hospital cost containment and long-term sustainability.

    Among the factors providers consider for antibiotics and opioids are: the type of infection, risk factors, and duration of therapy.

    Panelists include Martha Tran, Pharm.D., Senior Director of Customer Operations at Inovalon, and Josh Caraccio, Pharm.D., BCPS, BCIDP, Principal Implementation Engineer at Inovalon. Arundhati Parmar, Editor-in-Chief of MedCity News, will moderate.

    Panelists will also explore how near real-time surveillance, smart risk prioritization, and closed-loop intervention are shifting stewardship programs to proactive, technology-enabled decision-making that lets pharmacists work at the top of their license.

    They will also discuss what it means to be a responsible steward of opioids and other strong medications at a hospital in the current healthcare climate.

    Among the takeaways from the webinar are:

    ∎ Explain how stewardship programs contribute to cost containment and health-system resilience.
    ∎ Identify the technology shift underway in stewardship programs from retrospective, dashboard-driven review to near real-time surveillance, smart risk prioritization, and closed-loop action.
    ∎ Recognize the shared playbook between antibiotic and opioid stewardship, and evaluate how surveillance, prioritization, and intervention workflows can be applied across both programs to reduce manual burden and free up pharmacist time.

    To register for this webinar, fill in the form below: